Home/Sponsors Directory

Janssen Research & Development, LLC

Expanded Access Intelligence

Active EAPs on ClinicalTrials.gov

Score contribution: 60 — 1 supporting sources.

Score 601 references
Featured Reference
Pre-Approval Expanded Access Study for TAR-200 Treating Physician UseOpens in new window

Conditions: Non-Muscle Invasive Bladder Neoplasms

Past EAPs on ClinicalTrials.gov

Score contribution: 40 — 18 supporting sources.

Score 4018 references
Featured Reference
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care TreatmentOpens in new window

Conditions: Sarcoma

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician UseSource

Conditions: Healthy

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerSource

Conditions: Metastatic Non-Small Cell Lung Cancer

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple MyelomaSource

Conditions: Multiple Myeloma

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple MyelomaSource

Conditions: Multiple Myeloma

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple MyelomaSource

Conditions: Relapsed or Refractory Multiple Myeloma

Partner with Right2Hope

Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.

Talk to Our TeamExplore Programs